MDxHealth SA Stock

Equities

MDXH

BE0974461940

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-09 pm EDT 5-day change 1st Jan Change
2.9 USD -3.33% Intraday chart for MDxHealth SA -2.36% -26.40%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2023 64.39M 69.42M Sales 2024 * 78.66M 84.81M Capitalization 76.17M 82.12M
Net income 2023 -39M -42.05M Net income 2024 * -26M -28.03M EV / Sales 2023 1.51 x
Net cash position 2023 * - 0 Net Debt 2024 * 103.27 111.34 EV / Sales 2024 * 0.97 x
P/E ratio 2023
-2.37 x
P/E ratio 2024 *
-2.98 x
Employees 255
Yield 2023 *
-
Yield 2024 *
-
Free-Float 97.37%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.33%
1 week-2.36%
Current month+16.00%
1 month+16.47%
3 months-18.31%
6 months-3.97%
Current year-26.40%
More quotes
1 week
2.79
Extreme 2.79
3.20
1 month
2.21
Extreme 2.21
3.20
Current year
2.21
Extreme 2.21
4.64
1 year
2.21
Extreme 2.21
4.64
3 years
0.00
Extreme 0
17.80
5 years
0.00
Extreme 0
17.80
10 years
0.00
Extreme 0
62.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 19-02-17
Director of Finance/CFO 50 19-07-21
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member 74 21-09-28
Director/Board Member 53 20-07-29
Director/Board Member 59 17-10-31
More insiders
Date Price Change Volume
24-05-08 3 -3.54% 34,094
24-05-07 3.11 -0.64% 11,373
24-05-06 3.13 -0.32% 46,101
24-05-03 3.14 +5.72% 169,445
24-05-02 2.97 +11.24% 120,390

Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm EDT

More quotes
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3 USD
Average target price
7.25 USD
Spread / Average Target
+141.67%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW